Novel Antibacterial Agents
This book was devoted to the latest advances achieved in the antibacterial field, with a focus on the recent efforts made to develop new antimicrobial agents with novel modes of action, and a perspective on future directions of this line of research. Antimicrobial resistance has become a major threa...
Saved in:
| Other Authors: | , |
|---|---|
| Format: | Book Chapter |
| Published: |
Basel
MDPI - Multidisciplinary Digital Publishing Institute
2022
|
| Subjects: | |
| Online Access: | Get Fullteks DOAB: description of the publication |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| LEADER | 07072naaaa2201861uu 4500 | ||
|---|---|---|---|
| 001 | doab_20_500_12854_78739 | ||
| 005 | 20220224 | ||
| 020 | |a books978-3-0365-2860-1 | ||
| 020 | |a 9783036528601 | ||
| 020 | |a 9783036528618 | ||
| 024 | 7 | |a 10.3390/books978-3-0365-2860-1 |c doi | |
| 041 | 0 | |a English | |
| 042 | |a dc | ||
| 072 | 7 | |a GP |2 bicssc | |
| 100 | 1 | |a Meneghetti, Fiorella |4 edt | |
| 700 | 1 | |a Barlocco, Daniela |4 edt | |
| 700 | 1 | |a Meneghetti, Fiorella |4 oth | |
| 700 | 1 | |a Barlocco, Daniela |4 oth | |
| 245 | 1 | 0 | |a Novel Antibacterial Agents |
| 260 | |a Basel |b MDPI - Multidisciplinary Digital Publishing Institute |c 2022 | ||
| 300 | |a 1 electronic resource (409 p.) | ||
| 506 | 0 | |a Open Access |2 star |f Unrestricted online access | |
| 520 | |a This book was devoted to the latest advances achieved in the antibacterial field, with a focus on the recent efforts made to develop new antimicrobial agents with novel modes of action, and a perspective on future directions of this line of research. Antimicrobial resistance has become a major threat to global health, and the twenty-two published articles here reported put in evidence that the discovery and development of new antibiotics are extremely challenging. The antimicrobial research covers a wide area, spanning from the design of new compounds, also supported by molecular modeling techniques, their synthesis and characterization, and biological tests.In this context, the current crisis caused by the COVID-19 pandemic, but also older threats, such as the human immunodeficiency virus or the hepatitis C virus, require greater attention than ever.The research works described in this book provide an extremely useful example of the results achieved in the field of antibacterial drug development. The search for new chemical entities was approached starting from both natural and synthetic compounds and addressing different targets. In addition, recent findings were presented and discussed highlighting the strategies to fight bacterial resistance. Detailed references to the state-of-the-art can be found in this book.We strongly encourage the wide group of readers to explore the book that we are presenting, to get inspired to develop new approaches for the diagnosis and treatment of antibacterial diseases, and to circumvent resistance issues. | ||
| 540 | |a Creative Commons |f https://creativecommons.org/licenses/by/4.0/ |2 cc |4 https://creativecommons.org/licenses/by/4.0/ | ||
| 546 | |a English | ||
| 650 | 7 | |a Research & information: general |2 bicssc | |
| 653 | |a saccharin | ||
| 653 | |a tetrazole | ||
| 653 | |a 1,3,4-thiadiazole | ||
| 653 | |a H7PX glioma cells | ||
| 653 | |a antimicrobial screening | ||
| 653 | |a antioxidant capacity | ||
| 653 | |a oxidative stress | ||
| 653 | |a natural products | ||
| 653 | |a medicinal plants | ||
| 653 | |a anti-infective agents | ||
| 653 | |a alternative infection models | ||
| 653 | |a antibacterial | ||
| 653 | |a anticancer | ||
| 653 | |a GC-MS | ||
| 653 | |a LIBS | ||
| 653 | |a Moringa oleifera | ||
| 653 | |a seed extract | ||
| 653 | |a MRSA | ||
| 653 | |a marine bisindole alkaloids | ||
| 653 | |a antibiofilm activity | ||
| 653 | |a adjuvants agents | ||
| 653 | |a VBNC cells | ||
| 653 | |a indole | ||
| 653 | |a thioxothiazolidine | ||
| 653 | |a antibacterial activity | ||
| 653 | |a antifungal activity | ||
| 653 | |a computer-aided prediction | ||
| 653 | |a docking | ||
| 653 | |a Mur B | ||
| 653 | |a CYP 51 | ||
| 653 | |a plant compounds | ||
| 653 | |a diarrhea | ||
| 653 | |a selectivity | ||
| 653 | |a compounds screening | ||
| 653 | |a quorum sensing inhibition | ||
| 653 | |a molecular docking | ||
| 653 | |a AMP | ||
| 653 | |a antimicrobial activity | ||
| 653 | |a antiviral activity | ||
| 653 | |a bacteriocin | ||
| 653 | |a COVID-19 | ||
| 653 | |a disinfectant | ||
| 653 | |a Lactobacillus plantarum | ||
| 653 | |a plantaricin | ||
| 653 | |a carbon nanotubes | ||
| 653 | |a quaternary ammonium groups | ||
| 653 | |a hyperbranched dendritic polymers | ||
| 653 | |a antibacterial properties | ||
| 653 | |a anti-cyanobacterial properties | ||
| 653 | |a 3D-printing | ||
| 653 | |a dental polymer | ||
| 653 | |a antibacterial agent | ||
| 653 | |a coating | ||
| 653 | |a mesoporous silica nanoparticles | ||
| 653 | |a polydimethylsiloxane | ||
| 653 | |a Leishmania tropica and infantum | ||
| 653 | |a antileishmanial agents | ||
| 653 | |a lucanthone analogues | ||
| 653 | |a amitriptyline analogues | ||
| 653 | |a quinolizidine-derived compounds | ||
| 653 | |a molecular modelling studies | ||
| 653 | |a covalent inhibitor | ||
| 653 | |a MurA | ||
| 653 | |a cyclobutenaminone | ||
| 653 | |a irreversible | ||
| 653 | |a methicillin-resistant Staphylococcus aureus | ||
| 653 | |a essential oils | ||
| 653 | |a Origanum majorana | ||
| 653 | |a Rosmarinus officinalis | ||
| 653 | |a Thymus zygis | ||
| 653 | |a biofilm inhibition and eradication | ||
| 653 | |a urushiol | ||
| 653 | |a 3-pentylcatechol | ||
| 653 | |a 3-pentadecylcatechol | ||
| 653 | |a Helicobacter pylori | ||
| 653 | |a antimicrobial | ||
| 653 | |a triple therapy | ||
| 653 | |a atopic dermatitis | ||
| 653 | |a skin barrier | ||
| 653 | |a cutaneous dysbiosis | ||
| 653 | |a Staphylococcus aureus | ||
| 653 | |a microbial therapy | ||
| 653 | |a drug delivery systems | ||
| 653 | |a tris(1H-indol-3-yl)methylium | ||
| 653 | |a turbomycin | ||
| 653 | |a indole derivatives | ||
| 653 | |a antibacterial action | ||
| 653 | |a overcoming of drug resistance | ||
| 653 | |a biological activities | ||
| 653 | |a essential oil | ||
| 653 | |a extract | ||
| 653 | |a Thymus mastichina | ||
| 653 | |a imidazole and imidazolium salts | ||
| 653 | |a amino acid | ||
| 653 | |a antibacterial agents | ||
| 653 | |a aggregation | ||
| 653 | |a lipophilicity | ||
| 653 | |a antimicrobial peptide | ||
| 653 | |a biomembranes | ||
| 653 | |a ESKAPE | ||
| 653 | |a antibiotic resistance | ||
| 653 | |a NMR | ||
| 653 | |a molecular dynamics | ||
| 653 | |a biophysics | ||
| 653 | |a sequence alignment | ||
| 653 | |a lytic infection | ||
| 653 | |a antibiotic-resistance | ||
| 653 | |a Mycobacterium tuberculosis | ||
| 653 | |a Acinetobacter baumannii | ||
| 653 | |a Pseudomonas aeruginosa | ||
| 653 | |a phage production | ||
| 653 | |a magistral phage | ||
| 653 | |a pulmonary delivery | ||
| 653 | |a oral administration | ||
| 653 | |a topical delivery | ||
| 653 | |a Pinus cembra L. | ||
| 653 | |a Pinus mugo Turra | ||
| 653 | |a Picea abies L. | ||
| 653 | |a Abies alba M. | ||
| 653 | |a chemical investigation | ||
| 653 | |a HS-GC/MS | ||
| 653 | |a antioxidant activity | ||
| 653 | |a tuberculosis | ||
| 653 | |a mycobactins | ||
| 653 | |a furan | ||
| 653 | |a siderophores | ||
| 653 | |a drug design | ||
| 653 | |a bioisosterism | ||
| 653 | |a drug resistance | ||
| 653 | |a n/a | ||
| 856 | 4 | 0 | |a www.oapen.org |u https://mdpi.com/books/pdfview/book/4830 |7 0 |z Get Fullteks |
| 856 | 4 | 0 | |a www.oapen.org |u https://directory.doabooks.org/handle/20.500.12854/78739 |7 0 |z DOAB: description of the publication |